27 Jul 2022 10:30
Β
Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Β
Block Listing Six Monthly Return
Β
Induction Healthcare (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:
Β
Name of applicant: | Induction Healthcare Group PLC Β LEI: 213800RY96GCZQW5TP19 Β | ||||
Name of scheme: | The Induction Healthcare NTA Share Option Plan Β | ||||
Period of return: Β | Β From: | 26/01/2022 | To: | 26/07/2022 Β | |
Number and class of securities originally admitted and the date of admission Β | 3,500,000 ordinary shares on 26 July 2021 | ||||
Balance of unallotted securities under scheme(s) from initial application: Β | 3,500,000 | ||||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Β | nil | ||||
Less: Number of securities issued/allotted under scheme(s) during the period: Β | 396,567 | ||||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: Β | 3,103,433 | ||||
Contact: | Alison Talbot, Company Secretary +44 (0) 3339 398 091 | ||||
Β
ENQUIRIES
Β
Induction James Balmain, Chief Executive Officer Guy Mitchell, Chief Financial Officer | Via Walbrook PR Ltd: induction@walbrookpr.com |
Β | |
Singer Capital Markets (Nominated Adviser and Broker) | +44 (0) 20 7496 3000 |
Philip Davies / Kailey Aliyar | Β |
Β | |
Walbrook PR LtdΒ | induction@walbrookpr.com |
Paul McManus / Alice Woodings | Mob: +44(0)7980 541 893 / +44 (0)7407 804 654 |
Β
Β
Β
About Induction - www.inductionhealthcare.com
Β
Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.
Β
Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.Β
Β
Follow the stocks